Bioluminescent Probe Logic Gating for In Vivo CSC Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for in vivo detection of cancer stem cells (CSCs) using ALDH1A1 biomarkers are limited by off-target activation from normal stem cells and background interference, making accurate detection challenging.
Innovation Solution
A bioluminescent probe that is sequentially activated by acidic environments and ALDH1A1 activity, producing a bioluminescent signal only when both conditions are met, minimizing off-target detection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If small-molecule fluorescent indicators such as ALDEFLUOR are used to detect ALDH1A1 in live animals, then detection capability is improved, but off-target staining occurs due to prevalence of ALDH in the body and cross-reactivity with non-ALDH1A1 isoforms
Solution Approach 1:
The patent changes the detection modality from fluorescence to bioluminescence, and modifies the probe structure to use a luciferin derivative coupled to a specific ALDH1A1 substrate. This parameter change enables isoform-specific detection through the unique catalytic mechanism of ALDH1A1, eliminating cross-reactivity with other ALDH isoforms while maintaining detection sensitivity in live animals
Solution Approach 2:
The patent introduces a luciferin-based probe as an intermediary that specifically interacts with ALDH1A1. The probe acts as a mediator that converts ALDH1A1 enzymatic activity into a bioluminescent signal, providing selective detection without the off-target effects seen with fluorescent indicators. The probe structure includes a luciferin moiety coupled to a substrate that is specifically processed by ALDH1A1
2Reliability
If fluorogenic (turn-on) probes with ALDH1A1 isoform selectivity are used, then isoform specificity is improved, but background interference from autofluorescence limits detection to cell cultures, excised tissue samples, or superficially within tumors
Solution Approach 1:
The patent replaces the fluorescence detection mechanism with a bioluminescence mechanism. Instead of using fluorogenic probes that rely on fluorescence emission (which suffers from autofluorescence background), the invention uses a luciferin-based probe that generates light through a chemical reaction catalyzed by ALDH1A1 followed by luciferase activity. This substitution eliminates autofluorescence background interference entirely, enabling deep-tissue in vivo detection while maintaining isoform selectivity
3Object-affected harmful factors
If bioluminescence imaging is used, then background interference is reduced, but detection sensitivity is limited without biomarker-responsive probes
Solution Approach 1:
The patent employs a two-step preliminary action mechanism: first, the probe is activated by ALDH1A1 enzymatic processing, and second, the activated probe undergoes luciferase-catalyzed oxidation to generate the bioluminescent signal. This preliminary activation step ensures that bioluminescence is only produced where ALDH1A1 is present, dramatically enhancing detection sensitivity for rare CSC populations while maintaining the low-background advantage of bioluminescence imaging
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The probe effectively distinguishes CSCs from normal stem cells, providing accurate in vivo detection and reducing background interference, demonstrated in various cancer cell lines and murine models.
Implementation Method 1
The probe must first respond to acid to become a substrate for ALDH1A1
Implementation Method 2
the aldehyde is oxidized by the ALDH to liberate a carboxylic acid substrate for luciferase
Implementation Method 3
a luciferase substrate is liberated that is oxidized to yield a bioluminescent signal
Data Source
AI summary
In this work, we have developed a luciferin derivative, AlDeLuc, the first logic-gated bioluminescence probe for cancer stem cells (CSCs) that is sequentially activated by acidic environments and ALDH1A1 activity. The reliance on these two biomarkers is critical to ensure that off-target detection of non-CSCs within the body is minimized. Beyond demonstrating efficacy in multiple cancer cell lines and a murine model of breast cancer, we employed AlDeLuc to investigate how the CSC population is altered by the inflammatory status of a tumor through a high-fat diet. The implication of this work provides a molecular link between obesity, inflammation, and tumor progression.